For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
A Single Dose of Recombinant Activated Factor VII (NovoSeven®) Did Not Impair the Function of the Coronary Artery Bypass Grafts – Successful Treatment of Critical Bleeding after Cardiac Surgery in Two CasesPfau G.a · Schilling T.a · Kozian A.a · Huth C.b · Schneemilch C.E.a · Heim M.U.c
aDepartment of Anaesthesiology and Intensive Care Medicine, bDepartment of Cardiovascular and Thoracic Surgery, cInstitute of Transfusion Medicine and Immunohaematology, Otto-von-Guericke-University Magdeburg, Germany
Bleeding disorders and hemorrhages cause considerable morbidity and mortality in cardiac surgical patients. Possible thromboembolic complications make the use of recombinant activated factor VII (rFVIIa) in the treatment of bleeding after cardiac surgery controversial. Case Reports: We describe 2 patients who experienced intractable bleeding after open heart surgery with the use of cardiopulmonary bypass. Bleeding was successfully treated by a single dose (90 γg/kg) of rFVIIa without affecting the patency of the grafts. Conclusion: rFVIIa may provide an opportunity for an effective treatment of serious bleeding episodes both during cardiac surgery and in the postoperative course.